Thyroid cancer patients with a high probability of harboring TERT promoter mutations can thus be screened for confirmative TERT promoter mutation testing, such as real-time PCR or next-generation sequencing, which can ultimately reduce the medical costs shouldered by them. This evidence concerns the gene TERT and thyroid cancer.